MiR-193a-5p Targets the Coding Region of AP-2α mRNA and Induces Cisplatin Resistance in Bladder Cancers
- PMID: 27698912
 - PMCID: PMC5039396
 - DOI: 10.7150/jca.15620
 
MiR-193a-5p Targets the Coding Region of AP-2α mRNA and Induces Cisplatin Resistance in Bladder Cancers
Abstract
Transcription factor AP-2 alpha (AP-2α or TFAP2A) is a newly identified prognostic marker of chemotherapy; its expression is positively correlated with chemosensitivity and survival of cancer patients. Using computational programs, we predicted that the coding region of AP-2α gene contains a potential miRNA response element (MRE) of miR-193a-5p, and the single nucleotide polymorphism (SNP) site (c.497A>G, rs111681798) resides within the predicted MRE. The results of luciferase assays and Western blot analysis demonstrated that miR-193a-5p negatively regulated the expression of AP-2α proteins, but have no influence on the mutant AP-2α (c.497A>G). Infection with lentiviral AP-2α gene or miR-193a-5p inhibitor in the bladder cancer cells decreased migration and cisplatin resistance, while knockdown of AP-2α gene or overexpression of miR-193a-5p in the urothelial cell line SV-HUC-1 increased migration and cisplatin resistances. We concluded that miR-193a-5p induced cisplatin resistance by repressing AP-2α expression in bladder cancer cells.
Keywords: AP-2α; bladder cancer; cisplatin resistance; miR-193a-5p; single nucleotide polymorphism..
Conflict of interest statement
The authors have declared that no competing interest exists.
Figures
              
              
              
              
                
                
                
              
              
              
              
                
                
                
              
              
              
              
                
                
                
              
              
              
              
                
                
                References
- 
    
- Solomon JP, Hansel DE. Morphologic and Molecular Characteristics of Bladder Cancer. Surg Pathol Clin. 2015;8:663–76. - PubMed
 
 - 
    
- Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF. et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013;63:58–66. - PubMed
 
 - 
    
- Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN. et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015;121:2586–93. - PubMed
 
 - 
    
- Ecke TH. Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer. Adv Exp Med Biol. 2015;867:293–316. - PubMed
 
 
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
